NMD4C Early Career Award Nominations Extended
We have extended the nomination submission deadline for our NMD4C Early-Career Investigator Awards! The new deadline is January 13th, 2023.
This initiative will allow NMD4C early-career members to be nominated for one of four awards, celebrating excellence and contribution to the neuromuscular field in both clinical and basic science streams.
The four early-career award categories that will be awarded for 2022 are:
- Early Career Researcher of the Year (Biomedical)
- Early Career Researcher of the Year (Clinical)
- Publication of the Year (Biomedical)
- Publication of the Year (Clinical)
If you wish to nominate yourself or an individual for any of these awards, please submit the following information via the nomination form here: https://www.surveymonkey.ca/r/NMD4C-ECawards.
You will be asked to include:
- Category for which you are nominating the individual.
- Brief bio sketch of the nominee. (any kind of biosketch accepted)
- Up to three clinical or research milestones of the nominee.
- Brief paragraph highlighting the achievements of the individual, and why you think they should receive the award.
- (For publication of the year biomedical/clinical) A PDF copy of the full publication you wish to nominate. *Publications from November 2021 – Present will be eligible.
Please complete this nomination form before the deadline of January 13, 2023 at 11:59pm ET.
The awards will be announced in January 2023 alongside the NMD4C/MDC neuromuscular clinical and postdoctoral research fellowships. If you have any questions, please feel free to reach out to communications coordinator James Davis at !
To be eligible for this award you must fall within the CIHR early-career criteria as being within five years of the date of a first independent appointment, and be a member of the NMD4C (if you are not a member, you can sign up here!)
Read next...
A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada
Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.
New Best Practice Recommendations for SBMA Care in Canada
Congratulations to Dr. Kerri Schellenberg, the team of Canadian experts, NMD4C Steering Committee members and Investigators, on publishing the first Canadian SBMA care guidelines!
Advancing Neuromuscular Research and Care: Highlights from the 2025 NMD4C Annual Meeting
On September 11, NMD4C hosted its 2025 Annual Meeting in Ottawa, bringing together clinicians, researchers, trainees, and partners for a full day of collaboration, strategic dialogue, and community-building.
NMD4C Hosts Inaugural Clinical Summer School to Empower Canada’s Future Neuromuscular Leaders
On September 10–11, NMD4C hosted its inaugural Clinical Summer School in Ottawa, bringing together 19 neuromuscular clinical fellows from across Canada for two days of hands-on training, mentorship, and networking. Led by national experts and co-chaired by Drs. Gordon Jewitt and Marianne Nury, the program complemented NMD4C’s accredited lecture series and fostered peer connection through dedicated community-building sessions.
2026 Neuromuscular Postdoctoral Research Fellowships Funding Competition is Now Open!
Apply Or Share this opportunity with the trainees in your network — Deadline: October 14, 2025. Hosted by Neuromuscular Disease Network for Canada (NMD4C) and Muscular Dystrophy Canada (MDC)
Announcing the 2026 Neuromuscular Clinical Fellowship Award Recipients
We are excited to share that the 2026 Neuromuscular Clinical Fellowship Awards have been awarded! These fellowships strengthen clinical training in neuromuscular medicine and help prepare the next generation of specialists who will advance neuromuscular care across Canada.